ARDS · Aridis Pharmaceuticals, Inc. - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|
| Revenue | $3.09M | $1.53M | $1.00M | - | - |
| Cost of Revenue | - | - | - | - | - |
| Gross Profit | - | - | - | - | - |
| R&D | $25.92M | $36.94M | $16.96M | $24.08M | $17.44M |
| SG&A | $7.16M | $7.31M | $6.45M | $6.03M | $3.16M |
| Total Operating Expenses | $33.08M | $44.25M | $23.40M | $30.11M | $20.60M |
| D&A | $487.0K | $435.0K | $337.0K | $338.0K | $62.0K |
| Operating Income | ($29.99M) | ($42.71M) | ($22.40M) | ($29.09M) | ($19.74M) |
| Interest Expense | - | - | - | - | - |
| Income Tax | - | - | - | - | - |
| Net Income | ($30.37M) | ($42.19M) | ($22.33M) | ($29.68M) | ($24.66M) |
| EPS - Basic | ($1.62) | ($2.44) | - | - | ($164.98) |
| EPS - Diluted | - | ($2.44) | - | - | ($164.98) |
Balance Sheet
| Line item | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|
| Cash & Equivalents | $4.88M | $18.10M | $8.23M | $20.90M | $24.24M |
| Accounts Receivable | $1.00M | $0 | $0 | $0 | $1.66M |
| Inventory | - | - | - | - | - |
| Accounts Payable | $2.31M | $5.24M | $1.89M | $1.75M | $2.33M |
| Current Assets | $11.63M | $24.39M | $12.76M | $25.84M | $28.35M |
| Total Assets | $14.70M | $26.80M | $15.12M | $27.97M | $31.61M |
| Current Liabilities | $36.90M | $33.35M | $22.44M | $19.33M | $5.30M |
| Long-term Debt | - | - | - | - | - |
| Total Liabilities | $38.93M | $39.91M | $23.80M | $24.33M | $5.30M |
| Stockholders' Equity | ($24.23M) | ($13.11M) | ($8.68M) | $3.64M | ($45.12M) |
| Retained Earnings | ($195.67M) | ($165.29M) | ($123.10M) | ($100.77M) | ($71.09M) |
Cash Flow
| Line item | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|
| Operating Cash Flow | ($29.13M) | ($22.94M) | ($20.48M) | ($8.16M) | ($17.56M) |
| Investing Cash Flow | ($82.0K) | ($530.0K) | ($367.0K) | ($174.0K) | ($698.0K) |
| Financing Cash Flow | $14.78M | $34.72M | $8.68M | $4.99M | $21.06M |
| CapEx | $82.0K | $530.0K | $367.0K | - | $698.0K |
| Free Cash Flow | ($29.21M) | ($23.47M) | ($20.84M) | - | ($18.25M) |
Ratios
| Metric | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|
| Profitability | |||||
| Gross margin | - | - | - | - | - |
| Operating margin | -970.3% | -2782.5% | -2240.1% | - | - |
| EBITDA margin | -954.6% | -2754.1% | -2206.4% | - | - |
| Net margin | -982.6% | -2748.7% | -2233.3% | - | - |
| Free cash flow margin | -945.0% | -1528.7% | -2084.3% | - | - |
| FCF / Net income | 0.96 | 0.56 | 0.93 | - | 0.74 |
| R&D / Revenue | 838.7% | 2406.3% | 1695.6% | - | - |
| SG&A / Revenue | 231.7% | 476.2% | 644.5% | - | - |
| Effective tax rate | - | - | - | - | - |
| Return on assets | -206.7% | -157.5% | -147.7% | -106.1% | -78.0% |
| Return on equity | 125.3% | 321.8% | 257.3% | -816.3% | 54.6% |
| Return on invested capital | - | - | - | - | - |
| Liquidity | |||||
| Current ratio | 0.32 | 0.73 | 0.57 | 1.34 | 5.35 |
| Quick ratio | 0.32 | 0.73 | 0.57 | 1.34 | 5.35 |
| Cash ratio | 0.13 | 0.54 | 0.37 | 1.08 | 4.58 |
| Leverage | |||||
| Debt / Equity | - | - | - | - | - |
| Debt / Assets | - | - | - | - | - |
| Debt / EBITDA | - | - | - | - | - |
| Interest coverage | - | - | - | - | - |
| Equity multiplier | -0.61 | -2.04 | -1.74 | 7.69 | -0.70 |
| Liabilities / Assets | 2.65 | 1.49 | 1.57 | 0.87 | 0.17 |
| Efficiency | |||||
| Asset turnover | 0.21 | 0.06 | 0.07 | - | - |
| Inventory turnover | - | - | - | - | - |
| Days sales outstanding | 118d | 0d | 0d | - | - |
| Days inventory outstanding | - | - | - | - | - |
| Days payable outstanding | - | - | - | - | - |
| Cash conversion cycle | - | - | - | - | - |
| Valuation | |||||
| P / E | - | - | - | - | - |
| P / B | - | - | - | - | - |
| P / S | - | 13.9x | - | - | - |
| EV / EBITDA | - | - | - | - | - |
| Growth | |||||
| Revenue growth (YoY) | 101.4% | 53.5% | - | - | - |
| Revenue CAGR (3y) | - | - | - | - | - |
| Revenue CAGR (5y) | - | - | - | - | - |
| Gross profit growth (YoY) | - | - | - | - | - |
| Operating income growth (YoY) | 29.8% | -90.7% | 23.0% | -47.4% | - |
| Net income growth (YoY) | 28.0% | -88.9% | 24.8% | -20.4% | - |
| EPS growth (YoY) | - | - | - | - | - |
| EPS CAGR (3y) | - | - | - | - | - |
| EPS CAGR (5y) | - | - | - | - | - |
| FCF growth (YoY) | -24.5% | -12.6% | - | - | - |
| FCF CAGR (5y) | - | - | - | - | - |
| Book value growth (YoY) | -84.8% | -51.0% | - | - | - |
Stability scores
Altman Z′
FY 2022 · bankruptcy risk
-18.90
Distress
Private-firm variant - uses book equity instead of market cap. > 2.90 safe · 1.23-2.90 grey · < 1.23 distress.
Piotroski F-score
FY 2022 · 9-point quality
2/9
Weak
- ✗Net income positive
- ✗Operating cash flow positive
- ✗ROA improved YoY
- ✓Cash flow > net income
- -Long-term debt decreased
- ✗Current ratio improved
- -No share dilution
- -Gross margin improved
- ✓Asset turnover improved
Peer comparison
Same SIC group: Pharmaceutical Preparations
Comparing Aridis Pharmaceuticals against the 5 most active filers in the same SIC group.